Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.76 is 79% below its 5-year average of -1.54, near the low end of its 5-year range (-3.77–-0.33).
12.66% above its 12-month average of -3.16.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.30.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 10 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.76
EARNINGS PER SHARE (EPS) AVG TTM
-3.16
EARNINGS PER SHARE (EPS) AVG 3Y
-2.11
EARNINGS PER SHARE (EPS) AVG 5Y
-1.54
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+12.66%
CURRENT VS 3Y AVG
-30.65%
CURRENT VS 5Y AVG
-78.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Anteris Technologies Global Corp.
Market Cap
$734.10M
Earnings Per Share (EPS)
-2.76
TTM Avg
-3.16
3Y Avg
-2.11
5Y Avg
-1.54
Market Cap
$719.64M
Earnings Per Share (EPS)
-1.55
TTM Avg
-1.25
3Y Avg
-1.99
5Y Avg
-2.90
Market Cap
$749.55M
Earnings Per Share (EPS)
-1.41
TTM Avg
-1.23
3Y Avg
-0.97
5Y Avg
-1.16
Market Cap
$709.33M
Earnings Per Share (EPS)
1.24
TTM Avg
2.06
3Y Avg
1.25
5Y Avg
1.30
Market Cap
$767.46M
Earnings Per Share (EPS)
-4.74
TTM Avg
-5.08
3Y Avg
-296.60
5Y Avg
-1006.80
Market Cap
$698.60M
Earnings Per Share (EPS)
-141.65
TTM Avg
-20.37
3Y Avg
-24.20
5Y Avg
-22.76
Market Cap
$774.32M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
-1.23
5Y Avg
-1.23
Market Cap
$775.72M
Earnings Per Share (EPS)
-1.18
TTM Avg
-1.05
3Y Avg
-1.11
5Y Avg
-0.92
Market Cap
$776.24M
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.20
3Y Avg
-0.27
5Y Avg
-0.29
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | -2.76 | -3.16 | -2.11 | -1.54 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -1.55 | -1.25 | -1.99 | -2.90 |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -1.41 | -1.23 | -0.97 | -1.16 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 1.24 | 2.06 | 1.25 | 1.30 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -4.74 | -5.08 | -296.60 | -1006.80 |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -141.65 | -20.37 | -24.20 | -22.76 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | N/A | -1.23 | -1.23 | -1.23 |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -1.18 | -1.05 | -1.11 | -0.92 |
| Geron Corporation (GERN)vs › | $776.24M | -0.10 | -0.20 | -0.27 | -0.29 |
| Annexon, Inc. (ANNX)vs › | $688.14M | -1.16 | -1.18 | -1.68 | -2.29 |
Trailing EPS (TTM)
$-2.76
Forward EPS (Est.)
$-1.23
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.55 |
| 2024-12-31 | -3.77 |
| 2023-12-31 | -1.28 |
| 2022-12-31 | -0.85 |
| 2021-12-31 | -0.48 |
| 2020-12-31 | -0.33 |
